Zydus Cadila’s US arm -- Nesher Pharmaceuticals has received the final approval from the US Food and Drug Administration (USFDA) to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended Release Capsules, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.
The drug is indicated for the treatment of Attention-Deficit Hyperactivity Disorder which is a brain disorder characterized by an ongoing pattern of inattention and, or hyperactivity-impulsivity that interferes with functioning or development. It will be manufactured at Nesher Pharmaceuticals’ manufacturing facility located at St. Louis, MO, USA.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: